Heparin Crisis Leads To New U.S. FDA Policy On Consulting Outside Experts
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA's new policy for retaining outside experts in emergency situations calls for the agency to consider the risks posed by the collaboration as well as requirements for conflict-of-interest screening and disclosure
You may also be interested in...
Competition To Cooperation: Indian And Chinese Firms Agree On Draft MOU For Partnerships, Investments And GMP Training
MUMBAI - Intense price competition in key developed markets and common concerns for quality products and GMP issues is set to bring India and China together to boost collaborative efforts
Competition To Cooperation: Indian And Chinese Firms Agree On Draft MOU For Partnerships, Investments And GMP Training
MUMBAI - Intense price competition in key developed markets and common concerns for quality products and GMP issues is set to bring India and China together to boost collaborative efforts
Amphastar Lawsuit Over Heparin Shipments Suggests Lovenox ANDA Approval May Be Far Off
Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.